Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1632 (LINC01632) is a human gene that produces a long intergenic non-coding RNA transcript, placing it within the lincRNA family[5][1]. LincRNAs are autonomously transcribed RNAs longer than 200 nucleotides, situated between protein-coding genes, and representing a subfamily of long non-coding RNAs[3]. They typically regulate gene expression, impact chromatin architecture, and provide fine-tuning of transcriptional programs in a tissue- and context-specific manner[3][7]. The specific cellular, physiological, or disease functions of LINC01632 remain undefined in current accessible literature and databases, reflecting its poorly characterized status. There are no reported drug interactions, biomarker utility, or known adverse safety profiles, and it is not considered a current therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1632 (LINC01632).